especially if the current treatment isn’t effective. A 2022 study found that only 24.9% of patients remained on their prescribed migraine prophylactic after 24 months. Among all patients ...

Prophylactic cardiac treatment in DMD patients is associated with a 54% lower hazard of death, highlighting its potential survival benefit. Only 27.7% of DMD patients received prophylactic cardiac ...

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

It is indeed a landmark move. Bhutan has introduced pre-exposure prophylaxis, an oral medication that significantly reduces ...

Chiedza Makura only learned she had been dismissed from her nursing job when a WhatsApp message came through on the evening of January 28. The 37-year-old single mother of three worked as an HIV nurse ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.